Effect of metformin on patients with impaired glucose tolerance

Diabetic Medicine

Volumn 16, Issue 6, 1999, Pages 477-481

  Li, Chunlin L ^a   Pan, C Y ^a   Lu, J M ^a   Zhu, Y ^a   Wang, J H ^a   Deng, X X ^a   Xia, F C ^a   Wang, H Z ^a   Wang, H Y ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Glycaemic control; Impaired glucose tolerance; Insulin sensitivity; Metformin

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PLACEBOS;

EID: 0032758172     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00090.x     Document Type: Article

References (20)

1. 1 King H, Rewers M. WHO Ad Hoc Diabetes Reporting Group: Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993; 16: 157-177.
2. 2 Pan CY, Lu JM, Tian H, Kong XT, Lu XP, Yao C et al. Study of the prevalence of diabetes mellitus in adults in the Shougang corporation in Beijing. Diabetic Med 1996; 113: 663-668.
3. 3 Pan XR, Hu YH. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese Da Qing IGT and diabetes study. Diabetes Care 1993; 16: 150-156.
4. 4 Jarrett RJ. Associations beween cardiovascular disease and impaired glucose tolerance. IDF Bulletin 1996; 41: 8-10.
5. 5 Jarrett RJ, McCartney P, Keen H. The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normal glycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982; 22: 79-84.
6. 6 Keen H, Jarrett RJ, McCartney P. The ten year follow up of the Bedford survey (1962-72): glucose tolerance and diabetes. Diabetologia 1982; 22:73-78.
7. 7 Ramachandran A, Snehakatha C, Nalk RAS, Mohan V, Shobana R, Viswanthan M. Significance of impaired glucose tolerance in an Asian Indian population: a follow-up study. Diabetes Res Clin Pract 1986; 2: 173-178.
8. 8 Chunlin L, Juming L, Changyu P et al. Two-year follow-up for patients with impaired glucose tolerance. Chin J Endocrinol Metab 1997; 13: 104-107.
9. 9 Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-772.
10. 10 Campbell IW, Howlett HCS. Worldwide experience of metformin as an effective glucose lowering agent: a meta-analysis. Diabetes Metab Rev 1995; 11:S57-S62.
11. 11 Papoz L, Job O, Eschwege E, Aboulker S, Cubeau J, Pequignot G, et al. Effect of oral hypoglycemic drugs on glucose tolerance and insulin secretion in borderline diabetic patients. Diabetologia 1978; 15: 373-380.
12. 12 Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
13. 13 Hermann LS, Melander A. Biguanides: basic aspects and clinical uses. In: Alberti KGMM, Defronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus, 2nd edn. Chichester, UK: John Wiley & Sons Ltd, 1997: 841-864.
14. 14 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
15. 15 Scheen AJ, Letiexhe MR, Lefebvre PJ. Effect of metformin in obese patients with impaired glucose tolerance. Diabetes Metab Rev 1995; 11:S69-S80.
16. 16 Fontbonne A, Charles MA, Juhan-Vague I, BIGPRO Study Group. The effect of metformin on the metabolic abnormalities associated with upper body fat distribution. Diabetes Care 1996; 19: 920-926.
17. 17 Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulphonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 7: 1100-1109.
18. 18 Campbell IW, Menzies DG, Chalmers J, Mobain AM, Brown ZRF. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab 1994; 21: 394-400.
19. 19 Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993; 16: 621-629.
20. 20 Chiasson JL. Possible therapeutic approaches to impaired glucose tolerance. IDF Bull 1996; 41: 16-20.